(Q36430945)

14 August 2017

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer (English)

1 reference

14 August 2017

Pierga JY

1

1 reference

14 August 2017

Lainé-Bidron C

2

1 reference

14 August 2017

Beuzeboc P

3

1 reference

14 August 2017

De Crémoux P

4

1 reference

14 August 2017

Pouillart P

5

1 reference

14 August 2017

Magdelénat H

6

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

76

1 reference

14 August 2017

4

1 reference

14 August 2017

537-540

1 reference

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Report of the DNA Cytometry Consensus Conference.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Antineoplastic drug resistance and breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Cathepsin D in breast cancer: a tissue marker associated with metastasis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Prognostic value of the S-phase fraction of breast cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2227990

Drill biopsy and puncture biopsy for the determination of hormone receptors

21 September 2018

1 reference

12 December 2020

Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy

1 reference

12 December 2020

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

1 reference

12 December 2020

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis

1 reference

12 December 2020

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

12 December 2020

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

12 December 2020

Do we really need prognostic factors for breast cancer?

1 reference

12 December 2020

Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group

1 reference

12 December 2020

Breast tumour response to primary chemotherapy predicts local and distant control as well as survival

1 reference

12 December 2020

Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues

1 reference

12 December 2020

Proteases as prognostic markers in cancer

1 reference

12 December 2020

Cytological diagnosis by fine needle sampling without aspiration

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1997.421

1 reference

Dimensions Publication ID

14 August 2017

1051570235

0 references

Fatcat ID

release_7psxzy2ytjdyfpbppvkmmjdzmi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7psxzy2ytjdyfpbppvkmmjdzmi

24 November 2022

mapped directly with Wikidata item

1 reference

14 August 2017

PubMed publication ID

9275033

1 reference